Health Care and Diseases and Eli Lilly and Co. and R&D and Government Health Care and Drug discovery and Health Care Businesses and Health Care & Life Sciences and Health Care & Insurance and Pharmaceutical

Lilly letting U.S. researchers test failed compounds for new uses

May 3, 2012

More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.

If they do, the time to market will be shorter and the drugmakers, who retain ownership of the compounds, will share profits with the researchers, who keep intellectual property rights. Traditionally, companies spend about $2 billion and take 14 years to develop drugs, a so-called “valley-of-death” commitment that’s stalled progress as drugmakers move cautiously in deciding which illness to target.

The joint program, a first for the National Institutes of Health, is designed to lessen their risk, funded by $575 million in the United State's fiscal 2013 budget. The agency cited the HIV treatment AZT, created from failed attempts to treat cancer, in explaining the partnership.

“We need to generate more of these success stories in a more systematic manner,” NIH director Francis Collins said during a news conference announcing the agreements..

The compounds by Indianapolis-based Lilly, New York-based Pfizer and London-based AstraZeneca will make available have already been shown to be safe in humans.

“For us, there is just benefits, in a way,” said Jan Lundberg, executive vice president for science and technology at Lilly.

Drugmakers will have to provide the compounds to researchers, which may requiring manufacturing more of the substances, Lundberg said.

The companies also face costs for maintaining patents on the compounds and for gathering and transmitting clinical data to scientists, said Don Frail, vice president for science and new opportunities at London-based AstraZeneca.

“There’s not a shelf of discontinued compounds that you can just pull one off and give to somebody,” Frail said. Clinical supplies alone, should the compounds enter human trials, may cost as much as $1 million, he said.

Collins said he is hopeful the work will lead to new treatments for diseases of the central nervous system, which have proved so difficult to attack that drug companies are dissuaded from investing in them.

Rod Mackenzie, a senior vice president at Pfizer, said neurological diseases are “one of the great health crises we face across the globe.”

“We need to do better there,” he said.

Should the drugs prove effective against a new disease, the companies will have the option to develop them into a marketed product, the agency said. Taxpayers would get a financial benefit only if an NIH scientist is a researcher on one of the compounds. Then royalties would flow back to the U.S. agency.

“Americans are eagerly awaiting the next generation of cures and treatments to help them live longer and healthier lives,” said Health and Human Services Secretary Kathleen Sebelius, in a statement. “To accelerate our nation’s therapeutic development process, it is essential that we forge strong, innovative and strategic partnerships across government, academia and industry.”

The bottom-line benefit for the public is societal, Collins said. Diseases that don’t have treatments now may get one, he said.The drugmakers will give researchers access to the chemicals and related data, the NIH said in a statement.
 

ADVERTISEMENT

Recent Articles by Bloomberg News

Comments powered by Disqus